PE20030254A1 - Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido - Google Patents
Complejo que comprende factor inhibidor de osteoclastogenesis y polisacaridoInfo
- Publication number
- PE20030254A1 PE20030254A1 PE2002000579A PE2002000579A PE20030254A1 PE 20030254 A1 PE20030254 A1 PE 20030254A1 PE 2002000579 A PE2002000579 A PE 2002000579A PE 2002000579 A PE2002000579 A PE 2002000579A PE 20030254 A1 PE20030254 A1 PE 20030254A1
- Authority
- PE
- Peru
- Prior art keywords
- ocif
- osteoclasto
- complex
- acid
- polysaccharides
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 238000001179 sorption measurement Methods 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- -1 CARRAGENIN Substances 0.000 abstract 1
- 229920000045 Dermatan sulfate Polymers 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031252 Osteomyelitis Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 229920001277 pectin Polymers 0.000 abstract 1
- 235000010987 pectin Nutrition 0.000 abstract 1
- 239000001814 pectin Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001198985 | 2001-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030254A1 true PE20030254A1 (es) | 2003-03-19 |
Family
ID=19036337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000579A PE20030254A1 (es) | 2001-06-29 | 2002-06-27 | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20030045456A1 (enExample) |
| EP (1) | EP1270015A3 (enExample) |
| KR (1) | KR20030003124A (enExample) |
| CN (1) | CN1442201A (enExample) |
| AR (1) | AR034716A1 (enExample) |
| AU (1) | AU783126B2 (enExample) |
| BR (1) | BR0202439A (enExample) |
| CA (1) | CA2392383A1 (enExample) |
| CO (1) | CO5390084A1 (enExample) |
| CZ (1) | CZ20022231A3 (enExample) |
| HK (1) | HK1048762A1 (enExample) |
| HU (1) | HUP0202119A2 (enExample) |
| IL (1) | IL150448A0 (enExample) |
| MX (1) | MXPA02006511A (enExample) |
| NO (1) | NO20023144L (enExample) |
| PA (1) | PA8549401A1 (enExample) |
| PE (1) | PE20030254A1 (enExample) |
| PL (1) | PL354799A1 (enExample) |
| RU (1) | RU2232594C2 (enExample) |
| SG (1) | SG98059A1 (enExample) |
| SK (1) | SK9492002A3 (enExample) |
| ZA (1) | ZA200205164B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| IL142557A0 (en) | 1998-10-28 | 2002-03-10 | Snow Brand Milk Products Co Ltd | Remedies for bone metabolic errors |
| EP1270015A3 (en) * | 2001-06-29 | 2004-02-25 | Sankyo Company Limited | A complex comprising OCIF and Polysaccharide |
| PA8568001A1 (es) * | 2002-03-01 | 2003-11-12 | Sankyo Co | Composicion farmaceutica |
| US7585840B2 (en) * | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| BR0309095A (pt) | 2002-04-10 | 2005-02-09 | Applied Research Systems | Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica |
| WO2003103710A1 (ja) * | 2002-06-07 | 2003-12-18 | 三共株式会社 | 骨破壊の治療または予防剤組成物の併用効果 |
| RU2323227C2 (ru) * | 2003-03-24 | 2008-04-27 | Санкио Компани Лимитед | Полимерные модификаторы и фармацевтические композиции |
| KR100840830B1 (ko) * | 2006-09-03 | 2008-06-23 | 재단법인서울대학교산학협력재단 | 고분자 히알루론산을 포함하는 골흡수 저해용 조성물 |
| RU2370271C2 (ru) * | 2006-11-22 | 2009-10-20 | Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) | Способ обнаружения комплексов между гепаринами и поликатионами |
| ITMI20121316A1 (it) * | 2012-07-27 | 2014-01-28 | Altergon Sa | Complessi di condroitina ad assorbimento transcutaneo |
| CN115594776B (zh) * | 2022-09-19 | 2024-03-15 | 山东大学 | 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US181418A (en) * | 1876-08-22 | Improvement in gas apparatus | ||
| US31725A (en) * | 1861-03-19 | Improvement in cultivators | ||
| US216297A (en) * | 1879-06-10 | Improvement in ironing-stands | ||
| US4207A (en) * | 1845-09-27 | lewis | ||
| US139325A (en) * | 1873-05-27 | Improvement in carriage-springs | ||
| US45456A (en) * | 1864-12-13 | Improved apparatus for carbureting air | ||
| TW318142B (enExample) * | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| US5464815A (en) * | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US20030207827A1 (en) * | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| US6693175B2 (en) * | 1997-09-24 | 2004-02-17 | Sankyo Co., Ltd. | Method for diagnosing bone dysbolism |
| CA2335106A1 (en) * | 1998-06-15 | 1999-12-23 | Takeda Chemical Industries, Ltd. | Thienodipyridine derivatives, production and use thereof |
| IL142557A0 (en) * | 1998-10-28 | 2002-03-10 | Snow Brand Milk Products Co Ltd | Remedies for bone metabolic errors |
| CA2349406C (en) * | 1999-09-03 | 2011-01-11 | Amgen Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| WO2002026191A2 (en) * | 2000-09-28 | 2002-04-04 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| EP1270015A3 (en) * | 2001-06-29 | 2004-02-25 | Sankyo Company Limited | A complex comprising OCIF and Polysaccharide |
| PA8568001A1 (es) * | 2002-03-01 | 2003-11-12 | Sankyo Co | Composicion farmaceutica |
-
2002
- 2002-06-26 EP EP02254497A patent/EP1270015A3/en not_active Withdrawn
- 2002-06-26 CZ CZ20022231A patent/CZ20022231A3/cs unknown
- 2002-06-27 PE PE2002000579A patent/PE20030254A1/es not_active Application Discontinuation
- 2002-06-27 US US10/183,091 patent/US20030045456A1/en not_active Abandoned
- 2002-06-27 ZA ZA200205164A patent/ZA200205164B/xx unknown
- 2002-06-27 IL IL15044802A patent/IL150448A0/xx unknown
- 2002-06-28 NO NO20023144A patent/NO20023144L/no not_active Application Discontinuation
- 2002-06-28 RU RU2002117385/15A patent/RU2232594C2/ru not_active IP Right Cessation
- 2002-06-28 CA CA002392383A patent/CA2392383A1/en not_active Abandoned
- 2002-06-28 SG SG200203944A patent/SG98059A1/en unknown
- 2002-06-28 MX MXPA02006511A patent/MXPA02006511A/es unknown
- 2002-06-28 CO CO02056452A patent/CO5390084A1/es unknown
- 2002-06-28 AR ARP020102447A patent/AR034716A1/es unknown
- 2002-06-28 PA PA20028549401A patent/PA8549401A1/es unknown
- 2002-06-28 HU HU0202119A patent/HUP0202119A2/hu unknown
- 2002-06-28 BR BR0202439-0A patent/BR0202439A/pt not_active IP Right Cessation
- 2002-06-28 SK SK949-2002A patent/SK9492002A3/sk not_active Application Discontinuation
- 2002-06-28 PL PL02354799A patent/PL354799A1/xx not_active Application Discontinuation
- 2002-06-28 AU AU50719/02A patent/AU783126B2/en not_active Ceased
- 2002-06-29 KR KR1020020037598A patent/KR20030003124A/ko not_active Withdrawn
- 2002-06-29 CN CN02155849A patent/CN1442201A/zh active Pending
-
2003
- 2003-02-06 HK HK03100851.5A patent/HK1048762A1/en unknown
- 2003-02-11 US US10/364,045 patent/US20030139325A1/en not_active Abandoned
-
2005
- 2005-10-21 US US11/254,836 patent/US20060084595A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU783126B2 (en) | 2005-09-29 |
| HU0202119D0 (enExample) | 2002-08-28 |
| US20030045456A1 (en) | 2003-03-06 |
| BR0202439A (pt) | 2003-06-10 |
| AR034716A1 (es) | 2004-03-17 |
| CO5390084A1 (es) | 2004-04-30 |
| SK9492002A3 (en) | 2003-02-04 |
| ZA200205164B (en) | 2003-03-24 |
| CN1442201A (zh) | 2003-09-17 |
| NO20023144D0 (no) | 2002-06-28 |
| CZ20022231A3 (cs) | 2003-02-12 |
| US20060084595A1 (en) | 2006-04-20 |
| MXPA02006511A (es) | 2004-08-11 |
| EP1270015A3 (en) | 2004-02-25 |
| EP1270015A2 (en) | 2003-01-02 |
| RU2232594C2 (ru) | 2004-07-20 |
| NO20023144L (no) | 2002-12-30 |
| IL150448A0 (en) | 2002-12-01 |
| KR20030003124A (ko) | 2003-01-09 |
| AU5071902A (en) | 2003-01-02 |
| CA2392383A1 (en) | 2002-12-29 |
| PA8549401A1 (es) | 2003-07-28 |
| US20030139325A1 (en) | 2003-07-24 |
| HUP0202119A2 (hu) | 2003-04-28 |
| HK1048762A1 (en) | 2003-04-17 |
| SG98059A1 (en) | 2003-08-20 |
| RU2002117385A (ru) | 2004-01-27 |
| PL354799A1 (en) | 2002-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030254A1 (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido | |
| KR102236829B1 (ko) | 헵시딘 유사체 및 이의 용도 | |
| AU2001257321B2 (en) | Parathyroid hormone and parathyroid hormone-related protein antagonists | |
| Johansson et al. | Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37 | |
| Hackeng et al. | Total chemical synthesis of human matrix Gla protein | |
| KR20220075343A (ko) | 접합된 헵시딘 모방체 | |
| JP2017523959A (ja) | ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 | |
| ATE549028T1 (de) | Stabile analoga von glp-1 | |
| CY1116110T1 (el) | ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ | |
| CO5700784A2 (es) | Polipeptidos de virus de papiloma humano y composiciones in- munogenas | |
| JP2024520861A (ja) | 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 | |
| BR9609335B8 (pt) | Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. | |
| CA3189432A1 (en) | Conjugated hepcidin mimetics | |
| EA200701791A1 (ru) | Растворимые гликозаминогликаназы и способ получения и применения растворимых гликозаминогликаназ | |
| WO2004014940A3 (en) | PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR ß PROTEINS | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| EP2935311A1 (en) | Apj receptor agonists and uses thereof | |
| SE9901379D0 (sv) | Receptor structures | |
| CA3009834A1 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| BR0208183A (pt) | Peptìdeo modificado por wt1 | |
| BR0114994A (pt) | Composição de vacina | |
| DE60239763D1 (de) | Knochenpolypeptid-1 | |
| NO20081654L (no) | Stabiliserte GLP-1-analoger | |
| PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
| WO2015141819A1 (ja) | 長時間作用型アドレノメデュリン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |